RxDoctor Payments Data

Chrsitine Kakoulas, MD

Internal Medicine · New York, NYNPI 1447314596

Payments from drug & device makers

$1,585in general payments, 2019–2025

Across 18 payments — averaging $88.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$421
  • Amgen$249
  • Palette Life Sciences, Inc.$226
  • Cequr Corporation$160
  • Lilly USA, LLC$143
  • Gilead$143
  • plus $243 from 2 others

What the payments were for

  • Food & beverage$1,56299%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,585 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$11,813
Medicare patients
51
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$46,133
Rosuvastatin Calcium93$1,271
Levothyroxine Sodium64$574
Gabapentin11$409
Bupropion XlBupropion Hcl19$326
Metoprolol Succinate16$320
Escitalopram Oxalate25$296
ValacyclovirValacyclovir Hcl14$262
Alendronate Sodium25$259
Omeprazole21$251
Olmesartan Medoxomil24$231
Atorvastatin Calcium32$220
Amlodipine Besylate31$208
Trazodone Hcl13$160
Metformin Hcl ErMetformin Hcl13$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$143$46,13342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →